Cardio-oncology & otherCohort study
Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast Cancer Patients Receiving Adjuvant Therapy
- Cohort study
- OneFlorida+ clinical research network
- multivariable Gray's method
Study context
- Population
- Female breast cancer patients treated with adjuvant chemotherapy and targeted therapy after surgery, 2012–2022mean age 50.6 years
- Participants
- 2,050 patients
- Exposure
- Prefrail and frail vs robust
- Outcome
- Nonfatal adverse CV events (cardiotoxicity) during adjuvant therapy
Main finding
As reported in the abstract
Adverse CV events
Each group vs robustAdjusted subdistribution hazard ratio (95% CI)P value
Prefrail
1.35(1.06–1.71)
P = 0.015Frail
1.70(1.11–2.61)
P = 0.015Observational data: associations, not effects.
Further findings
| Outcome | adjusted sHR (95% CI) | P value | |
|---|---|---|---|
| Adverse CV events, non-Hispanic White (subgroup) — Prefrail vs Robust | 1.48 (1.04–2.11) | P = 0.031 | |
| Adverse CV events, non-Hispanic White (subgroup) — Frail vs Robust | 1.96 (1.10–3.50) | P = 0.022 | |
| Adverse CV events, Black (subgroup) — Prefrail vs Robust | 1.59 (1.06–2.37) | P = 0.024 | |
| Adverse CV events, Black (subgroup) — Frail vs Robust | 2.13 (1.11–4.10) | P = 0.023 | |
| 0.20.5125Adjusted subdistribution hazard ratio (log scale) |
Adverse CV events, other racial/ethnic groups (subgroup)
- No significant differences
Original publication
Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast Cancer Patients Receiving Adjuvant Therapy. JACC CardioOncol. Published 7 January 2025. doi:10.1016/j.jaccao.2024.10.012
Summarised from the published abstract; every number is checked against it